AcelRx 'Reenergized' By EU Zalviso Approval; Royalty Sell-Off To Fund US Fight Back
This article was originally published in Scrip
AcelRx Pharmaceuticals Inc., which suffered a major setback last year when the US FDA refused to approve its lead product Zalviso (sufentanil sublingual tablets) for the treatment of post-operative pain, has been 'reenergized' by news that the product has been approved in Europe, management told Scrip. This follows news from earlier this week that AcelRx has sold the majority of the expected royalty stream from the sales of Zalviso in the EU to PDL BioPharma. AcelRx's commercial partner in the EU is Grunenthal GmbH.
You may also be interested in...
Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.
AcelRx reports fast-acting, pain-reducing data for ARX-04 in emergency room-treated trauma patients, which is the setting that most closely resembles battlefield situations experienced by personnel in the US military – the Phase III program's co-funder.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.